Cross Q&A: Team Dana-Farber

Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.

Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.

Azacitidine/venetoclax improving EFS over chemotherapy in fit patients with AML is an “important outcome,” according to Amir T. Fathi, MD.

Poster presentations at SOHO 2026 may inform practice across acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia.

Combination approvals for revumenib and ziftomenib in relapsed/refractory acute myeloid leukemia may arrive before frontline approvals, according to Eunice Wang, MD.

Data from the phase 2 PARADIGM trial may support the use of less toxic, more gentle therapies for patients with acute myeloid leukemia.